Abstract

While the world awaits new treatments and vaccines for coronavirus disease 2019 (COVID-19), the health economics and outcomes research (HEOR) community is already examining various aspects of the novel coronavirus severe acute respiratory syndrome coronavirus 2 of the genus Betacoronavirus (SARS-CoV-2) pandemic. At this point, the emerging literature mainly considers the cost of the pandemic and health economic issues surrounding the development of policies. Some modeling work is being conducted to determine the potential value of future treatments or vaccines, and those models will no doubt be tailored and used to assess new health technologies as effectiveness data emerge.